Jecko Thachil/LinkedIn
Mar 9, 2026, 14:10
Jecko Thachil: The Journey of Protamine – From Heparin Reversal to Potential Gene Therapy Applications
Jecko Thachil, Consultant Haematologist at NHS, shared a post on LinkedIn about his recent article, adding:
“Protamine is a very useful drug in reversing heparin and has been used for several years.
How did its journey start from the discovery of DNA and now may be relevant for gene therapy?”
Title: Protamine—The Journey from DNA to Heparin Neutralization to Gene therapy
Author: Jecko Thachil
Read the Full Article on Seminars in Thrombosis and Hemostasis
Other posts featuring Jecko Thachil on Hemostasis Today.
-
Mar 9, 2026, 14:10Advocating for the Bleeding Disorders Community at NBDF 2026 Washington Days – Hemophilia of Georgia
-
Mar 9, 2026, 14:05Ramy Abdelnaby: The Impact of Multiterritory Brain Infarcts on Recurrent Stroke Risk and Anticoagulation Efficacy
-
Mar 9, 2026, 13:55Marios Georgakis: GLP-1 Receptor Agonism as a Promising Approach for cSVD
-
Mar 9, 2026, 13:54Ahmed Ibrahim: Optimal Antithrombotic Therapy for Secondary Stroke Prevention in Patients with AF and ASCVD
-
Mar 9, 2026, 13:49Rick Matthews: Looking Beyond Clot Clearance in Long-Term Management After DVT
-
Mar 9, 2026, 13:43Genetic Technologies for Hemophilia Information Sheet Now Available in French and Spanish – WFH
-
Mar 9, 2026, 13:38Challenges in Hemophilia Care and Access to Treatment in Pakistan – Hemophilia Welfare Society Karachi Pakistan
-
Mar 9, 2026, 05:13Nicola Hancock: Shaping the Future of Stroke Care and the Stroke Action Plan for Europe at ELASF 2026
-
Mar 8, 2026, 16:19Simon Senanu: Crossmatch Procedures and Advanced Troubleshooting